Spero Therapeutics Receives $30,000,000 Series A Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=bb31e81b-2f9b-4822-b8c2-d3b200204ea1 - Date
6/8/2015 - Company Name
Spero Therapeutics - Mailing Address
400 Technology Square 10th Floor Cambridge, MA 20139 USA - Company Description
Spero Therapeutics’ vision is to find, develop, and advance groundbreaking therapeutics to meet critical patient needs in infectious disease using a unique business and drug discovery model. Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. - Website
http://www.sperotherapeutics.com - Transaction Type
Venture Equity - Transaction Amount
$30,000,000 - Transaction Round
Series A - Proceeds Purposes
Spero plans to use the proceeds from this financing to advance the Potentiator franchise into clinical development by 2016, progress its anti-virulence program in partnership with Roche through the submission of an Investigational New Drug (IND) application, and develop additional programs in its pipeline focused on unmet medical needs in bacterial infections. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
